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Abstract
In addition to regulating reproductive functions in the brain and periphery, estrogen has trophic and
neuroprotective functions in the central nervous system (CNS). Estrogen administration has been
demonstrated to provide protection in several animal models of CNS disorders, including stroke,
brain injury, epilepsy, Parkinson’s disease, Alzheimer’s disease, age-related cognitive decline and
multiple sclerosis. Here, we use a model of toxin-induced oligodendrocyte death which results in
demyelination, reactive gliosis, recruitment of oligodendrocyte precursor cells and subsequent
remyelination to study the potential benefit of 17β-estradiol (E2) administration in male mice. The
results indicate that E2 partially ameliorates loss of oligodendrocytes and demyelination in the corpus
callosum. This protection is accompanied by a delay in microglia accumulation as well as reduced
mRNA expression of the pro-inflammatory cytokine, tumor necrosis factor alpha (TNFα), and
insulin-like growth factor-1 (IGF-1). E2 did not significantly alter the accumulation of astrocytes or
oligodendrocyte precursor cells, or remyelination. These data obtained from a toxin-induced, T cell-
independent model using male mice provide an expanded view of the beneficial effects of estrogen
on oligodendrocyte and myelin preservation.
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Interest in the use of sex hormones for therapy to treat multiple sclerosis (MS) comes from the
observation that disease is partially ameliorated during pregnancy. A large prospective study
of MS patients showed a significant decrease in disease relapses during pregnancy, especially
the third trimester, compared to the relapse rate in these same women before pregnancy
(Confavreux et al. 2003). In addition, the relapse rate significantly increased after delivery,
especially in the first 3 months post-partum, prior to returning to pre-pregnancy levels at 9–12
months. This finding suggests a protective role for pregnancy-related factors, one of which
could be sex steroids.
The data from animal models of demyelinating disease and in vitro studies provides evidence
for a potential benefit of estrogens. Two forms of estrogen, estriol and 17β-estradiol (E2), have
been shown to reduce clinical symptoms of experimental autoimmune encephalomyelitis
(EAE) (Bebo et al. 2001; Hoffman et al. 2001; Kim et al. 1999). Addition of E2 to rodent
primary oligodendrocyte cultures led to increased proliferation of oligodendrocyte precursors
and enhanced membrane sheet formation (Ghoumari et al. 2003; Jung-Testas et al. 1992;
Marin-Husstege et al. 2004). E2 also prevented toxin and oxygen-mediated death of
oligodendrocytes in culture and oxygen-mediated loss of myelin basic protein in neonatal rat
white matter (Gerstner et al. 2007; Takao et al. 2004). Furthermore, estrogens have anti-
inflammatory effects in CNS models, as reviewed in (Pozzi et al. 2006; Vegeto et al.). E2
inhibits expression of TNFα and several other inflammatory mediators in response to LPS or
proinflammatory cytokines in microglial cell cultures (Bruce-Keller et al. 2000; Drew and
Chavis 2000; Vegeto et al. 2006; Vegeto et al. 2001), and in the brain (Vegeto et al. 2006).
Furthermore, E2 and estrogen receptor ligands administered in mice with EAE prevented
axonal loss in the white matter and neuronal pathology in gray matter, highlighting the potential
benefit of estrogen in preserving neuronal integrity in demyelinating disease (Morales et al.
2006; Tiwari-Woodruff et al. 2007).
In an effort to determine whether estrogen is capable of influencing demyelinating disease in
vivo, we used the cuprizone model of oligodendrocyte death, demyelination and remyelination
in male C57BL/6 mice treated with E2 in the form of subcutaneously implanted E2 pellets.
We used male mice to avoid estrogen fluctuation during cycling in female mice and because
demyelination is well characterized in C57BL/6 males (Hiremath et al. 1998; Matsushima and
Morell 2001). Cuprizone causes death of oligodendrocytes, demyelination and infiltration of
reactive glia to the demyelinating site, accompanied by oligodendrocyte precursor cells (OPCs)
(Hiremath et al. 1998; Mason et al. 2000a; Matsushima and Morell 2001). Remyelination
occurs spontaneously by six weeks of treatment, and proceeds rapidly if cuprizone intoxication
is discontinued (Arnett et al. 2001; Mason et al. 2001a; Morell et al. 1998). Using this model,
we report that E2 is capable of partial amelioration of oligodendrocyte loss and demyelination,
but did not alter remyelination following discontinuation of cuprizone. Furthermore, E2
treatment resulted in a delay in microglia accumulation and a reduction in levels of IGF-1 and
TNFα mRNA. Thus, a protective effect of E2 in cuprizone-induced demyelination may occur
via multiple mechanisms, including enhancement of oligodendrocyte survival and reduction
of microglia activation within the lesion.
MATERIALS AND METHODS
Animals and cuprizone treatment
Adult male C57BL/6J mice were purchased from Jackson Laboratories (Bar Harbor, ME) and
used for experiments at 8 weeks of age. Mice were housed in DLAM facilities under sterile
pathogen-free conditions. To induce demyelination, cuprizone (oxalic bis
(cyclohexylidenehydrazide)) (Sigma-Aldrich) at a concentration of 0.125% was mixed into
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ground Purina mouse chow and fed ad libitum for 3 to 5 weeks. We found in a dose titration
that 0.125% cuprizone retained the ability to induce demyelination similar to our previous
studies using 0.2%; however, this concentration was optimal to assess the efficacy of E2
administration. Remyelination was assessed by returning the mice to a diet of normal chow for
one week following 6 weeks of cuprizone administration. Control mice (labeled “no
cuprizone”) were fed pelleted Purina chow and were sacrificed at the same time as the 5 week
cuprizone group. All animal use was performed in compliance with the NIH Guide for Care
and Use of Laboratory Animals and approved by the UNC-CH Institutional Animal Care and
Use Committee.
17β-estradiol administration
Continuous release 25 mg 17β-estradiol (E2) or placebo pellets (3×4 mm; Innovative Research
of America, Sarasota, FL) were implanted subcutaneously between the shoulder blades by
sterile surgical procedure under anesthesia. These pellets are designed to release continuously
over a 60 day period, at an approximate rate of 0.42 mg/day. Cuprizone treatment began 5 days
after implantation.
Serum 17β-estradiol measurement
Whole blood samples were obtained by cardiac puncture and serum isolated by centrifugation
at 2.7g after removal of the blood clot. The serum was stored at −80°C until use. E2 was
measured by radioimmunoassay (RIA) using the double antibody estradiol kit (cat# KE2D5,
Seimens, Los Angeles, CA) and following the manufacturer’s protocol.
Tissue Preparation
For histology, mice were deeply anesthetized using isoflurane and intracardially perfused with
0.15M phosphate buffer followed by 4% paraformaldehyde (PFA) solution. Brains were
removed, post-fixed overnight in PFA, and embedded in paraffin or post-fixed for 4 hours in
PFA, followed by 1–2 days in 30% sucrose, and then embedded in Tissue-Tek® O.C.T.™
freezing media (Sakura Finetek, Torrance, CA) and frozen on a bed of dry ice. Five μm paraffin
or frozen coronal brain sections were cut at the fornix region of the corpus callosum
(approximately Bregma −0.5mm to −0.7mm), corresponding to Figure 37 of The Mouse Brain
In Sterotaxic Coordinates (Franklin 2001).
For the isolation of mRNA, corpus callosum tissue was collected from gross coronal cuts at
approximately Bregma −0.25mm and −1.25mm. Sagittal cuts were then made through the
cingulum, medial to each lateral ventricle, followed by a cut above and below the corpus
callosum to remove the majority of cortex and fornix. This block of tissue was immediately
submerged in RNAlater solution (cat#AM7020, Applied Biosystems, Foster City, CA) and
after overnight 4°C incubation, stored at −80° C until use. The corpus callosum of five brains
was combined for each sample.
Luxol Fast Blue – Periodic Acid Schiff’s (LFB-PAS) stain
To examine demyelination and remyelination, paraffin or frozen sections were stained with
Luxol fast blue (Sigma, St. Louis, MI), which stains myelin blue, and periodic acid-Schiff
(Sigma, St. Louis, MI), which stains demyelinated axons pink. A blinded observer examined
the midline corpus callosum (as diagramed previously in Figure 1 of Mason et al. (Mason et
al. 2000a) using a didymium filter and 600× magnification. The sections were scored based
on the relative ratio of blue or pink fibers detected visibly by the observer, on a scale from 3
(complete myelination equal to an untreated mouse) to 0 (complete demyelination, as seen
during peak cuprizone demyelination at week 5).
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The detection of mature oligodendrocytes was performed with antibody to the Pi isoform of
glutathione S-transferase (GSTpi) (Biotrin, Newton, MA, no longer available). Paraffin or
frozen sections were permeabilized with 0.1% Triton X-100/2% normal goat serum in
phosphate-buffered saline (PBS) for 20 minutes at room temperature. Antigen retrieval to better
expose the antibody-binding epitope was performed with 0.1% calcium chloride/0.1% trypsin
in 0.05M Tris, pH 7.4 for 15 minutes at 37°C. Sections were rinsed in PBS and incubated with
anti-GSTpi antibody (1:1000) or isotype control overnight at 4° C.
Oligodendrocyte precursor cells were detected with a rabbit antibody to NG2, generously
supplied by Dr. W.B. Stallcup (Genomic Institute of Novartis Res. Foundation, CA). Five
micrometer frozen sections were fixed in 95% ethanol before being stored at −80 °C. Upon
removal from the freezer, sections were post-fixed in cold acetone, rinsed in potassium-
phosphate-buffered saline (KPBS), and blocked with 0.1% Triton X-100/5% normal goat
serum in KPBS for 1 hour at room temperature. Sections were then incubated with anti-NG2
antibody (1:500 in blocking solution) or isotype control overnight at 4° C.
Microglia/macrophages were detected with biotinylated lectin Ricinus communis agglutin-1
(RCA-1) (Vector Laboratories Inc, Burlingame, CA). Paraffin or frozen sections were
unmasked with 0.025% protease, type XIV (Sigma-Aldrich) for 2 minutes at 43° C. Following
a brief rinse in PBS, they were blocked with 0.1% Triton X-100/1% bovine serum albumin in
PBS for 1 hour at room temperature. Sections were then incubated with RCA-1, 1:500 in
blocking solution or blocking solution alone as a control, overnight at 4° C.
Astrocytes were detected with antibody to glial fibrillary acidic protein (GFAP) (Invitrogen).
Paraffin sections were rehydrated and unmasked with 0.025% protease, type XIV (Sigma-
Aldrich) for 2 minutes at 43° C. Following a brief rinse in PBS they were blocked with 0.1%
Triton X-100/2% normal goat serum in PBS for 1 hour at room temperature. Sections were
then incubated with anti-GFAP antibody (1:200) or isotype control overnight at 4° C.
Following incubation in the primary detection agent, all immunohistochemistry was completed
by first rinsing sections three times in PBS, then incubating for 1 hour at room temp with the
appropriate secondary antibody (1:400) conjugated to AlexaFluor (Molecular Probes, Eugene,
OR). After rinsing, sections were cover-slipped with Vectashield plus DAPI (Vector
Laboratories Inc, Burlingame, CA) to counter stain nuclei.
An Olympus (Melville, NY) BX40 microscope, Olympus DP70 digital camera and
ImageProPlus software (Media Cybernetics, Silver Spring, MD) were used to obtain images
from two sections per brain. All comparative analyses were focused in the corpus callosum
from two fields of view, one on each side of the midline, under 400× magnification. The images
of the fluorescent antibody-stained sections were overlayed with DAPI images and
immunohistochemically-positive cells which colocalized with a nucleus were quantified per
square mm by a blinded observer.
Real-time PCR
Corpus callosum tissue (see above) was pooled for 5 animals per treatment group. RNA was
obtained by manual homogenization using Potter-Elvehjem type PTFE pestle and glass tubes
(Kontes, Vineland, NJ) in Trizol (Invitrogen, Carlsbad, CA) and cleaned up with RNeasy Mini
kit (cat# 74104, Qiagen, Valencia, CA). TaqMan 5′ nuclease real-time PCR assays were
performed using an ABI Prism 7500 sequence-detection system (PE Applied Biosystems,
Foster City, CA) in the UNC Neuroscience Center Functional Genomics Core Facilty. For
IGF-1 analysis the Taqman® Gene Expression Assay system was used (ID#
Mm00439559_m1), which includes proprietary sequences (Applied Biosystems, Foster City,
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CA). For TNFα analysis custom oligonucleotide primer and TMRA™ probe sequences were





All statistical analyses were performed using GraphPad Prism 4.0 (GraphPad Software Inc, La
Jolla, CA). Comparisons between placebo and E2 treated mice were analyzed using two-tailed
Student’s t test. Differences were considered significant if p ≤ 0.05. Correlation analysis
between different biological measures of the E2-treated mice (for instance myelination score
and serum E2 levels) were performed using a two-tailed Spearman analysis and considered
significant if p ≤ 0.05.
RESULTS
Serum levels of E2 in mice implanted with continuous release hormone pellets
In order to determine the effect of E2 on demyelination and remyelination, male C57BL/6 mice
were implanted subcutaneously with continuous release placebo or pellets containing 25 mg
E2 designed to release a consistent amount of hormone over 60 days (0.42 mg/day). In order
to confirm the effectiveness of the implants, and to rule out an effect of cuprizone on serum
E2 levels, we measured E2 in serum at various timepoints following implantation and also,
following cuprizone exposure. Thus, blood was collected from a representative sample of E2
and placebo treated mice 4 days following implantation, at 3 and 5 weeks after initiation of
cuprizone feeding, and one week following cuprizone removal from the diet. Serum levels of
E2 were measured by RIA.
Serum E2 in male mice prior to implantation, or in placebo implanted mice was nearly always
below the detection limit of the RIA. When detectable, a range from 5–10pg/mL was found,
which is consistent with normal levels in males (data not shown). Four days after E2
implantation, serum E2 rose rapidly and reached an average of about 3000 pg/mL (Figure 1).
After 3 or 5 weeks of cuprizone treatment, average serum E2 was 4000 to 5000 pg/mL with
similar levels reached in the mice not receiving cuprizone. By the 6 weeks of cuprizone plus
1 week recovery time point, average serum E2 had diminished slightly to 3500 pg/mL. These
levels correspond to the lower range of E2 reported for pregnant mice (5000–10,000 pg/mL)
(Foster et al. 1983).
E2 partially protects against cuprizone-induced demyelination
The effect of E2 on demyelination was assessed by exposing mice to cuprizone five days after
implantation of placebo or E2 pellets. Mice were analyzed for demyelination after 3 or 5 weeks
of cuprizone treatment, when male C57BL/6 are known to be partially or fully demyelinated,
respectively (Hiremath et al. 1998). After 3 weeks of cuprizone administration, E2-treated mice
are significantly less demyelinated than placebo controls (p < 0.05; Figure 2A and 2B). This
effect continues at the 5 week time point in which the E2-treated mice showed significantly
less demyelination.
A visual analysis of the individual myelin scores during demyelination indicates that E2 was
effective at attenuating demyelination in some, but not all mice receiving it. To determine if
these “responders” represent a sub-population, we marked all data points from them with filled
circles (Figure 2B), and tracked them throughout the study. At the five week time point, there
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is a clear difference between mice that are almost fully demyelinated (open circles) and those
which had myelin scores greater than any of the placebo-treated mice (filled circles). Although
variability in myelin scores of placebo- treated mice at the 3 week time point is greater than at
5 week, there is still a population of E2-treated mice with higher myelin scores than mice
receiving placebo. The reason for the variability in the protective effect of E2 is unclear. We
speculate it could be a reflection of the amount of cuprizone ingested. However, potential
variation in exposre to cuprizone could not be confirmed as mass spectrometry of serum
samples was unable to detect cuprizone. Spearman correlation analysis indicated that
demyelination did not correlate with the level of serum E2 (p > 0.05), suggesting that varability
in E2 levels was not responsible for variability in the potency of E2 protection.
As expected, after 1 week of recovery from cuprizone, the placebo-treated mice began to
remyelinate substantially. However, the E2-treated mice displayed an average myelin score
very similar to their 5 week time point (Figure 2B). This suggested that remyelination may be
partly delayed in the E2-treated mice.
E2 preserves oligodendrocytes
In addition to myelin, the number of oligodendrocytes was examined in corpus callosum
sections by immunohistochemistry to detect the marker GSTpi, which allows visualization of
mature oligodendrocyte cell bodies (Figure 3A). Equal numbers of oligodendrocytes were
detected in E2-treated and placebo mice that did not receive cuprizone (Figure 3B). Similar to
myelin staining in histological sections in Figure 2B, E2-treated mice displayed preservation
of oligodendrocytes during demeylination, at both the 3 and 5 week time points. Compared to
placebo controls, there was nearly twice the number of surviving mature oligodendrocytes in
E2-treated mice at week 5 (p< 0.05; Figure 3A and 3B). This suggests that E2 at least partially
protects mature oligodendrocytes from cuprizone toxicity.
As stated previously, the E2-treated group of mice at week 5 in Figure 2B could be segregated
into E2 non-responders and E2 responders, the latter showing protection from demyelination.
E2 responders also showed a tendency for higher numbers of oligodendrocytes, indicative of
oligodendrocyte preservation (Figure 3B), particularly at the 5 week time point. Thus, E2
treatment inhibits demyelination and provides a protective effect for mature oligodendrocytes.
The number of mature oligodendrocytes during remyelination was also assessed in E2-treated
and placebo mice. One week after removal of cuprizone from the diet, oligodendrocyte
numbers were almost completely restored to levels observed in control mice not receiving
cuprizone. Although the number of mature oligodendrocytes appears lower in E2-treated mice
than placebo controls, the difference was not statistically significant (Figure 3B).
E2 does not affect the number of oligodendrocyte precursor cells in demyelinating/
remyelinating lesions of treated mice
In vitro studies indicate that E2 can promote proliferation of oligodendrocytes (Marin-Husstege
et al. 2004). During exposure to cuprizone, oligodendrocyte precursor cells (OPCs) proliferate
and accumulate in the demyelinated corpus callosum (Mason et al. 2000a). Therefore, we
hypothesized that numbers of OPCs would be greater in demyelinated lesions of E2-treated
mice. OPCs were detected by immunohistochemistry to the proteoglycan NG2. It is well
established that NG2-positive cells generate oligodendrocytes, however it has recently been
demonstrated that they can also generate protoplasmic astrocytes in the gray matter, and
potentially a small population of neurons in certain brain regions (reviewd in (Nishiyama et
al. 2009)). The suitability of NG2 as an OPC marker in the corpus callosum is supported by
findings from a genetic fate-mapping study using NG2-Cre-transgenic mice which showed that
astrocytes of the white matter were not generated from NG2 cells (Zhu et al. 2008).
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Furthermore, we have perfomed co-immunolabelling studies with NG2 and the astrocyte
marker GFAP and have not observed any co-localization (data not shown). Contrary to our
expectations, there was no statistically significant difference in numbers of OPCs in the lesions
of E2-treated mice compared to placebo, at any of the time points (Figure 4). However, fewer
OPCs accumulated in the corpus callosum of E2 responders (filled circles) when E2 was most
effective at reducing demyelination. Spearman correlation analysis indicates a significant
correlation between myelin score and OPC numbers at both 3wk (p = 0.0011) and 5wk (p =
0.0072) in E2-treated mice. During remyelinaton, one week after removal of cuprizone from
the diet, OPC numbers are reduced, consistent with differentiation to mature oligodendrocytes,
and there is no difference between placebo and E2-treated mice (Figure 4). Thus, although we
observed a correlation between reduced demyelination and fewer OPCs within the E2 group,
OPC numbers were not statistically different when compared to the placebo group.
Accumulation of microglia/macrophages is delayed in E2-treated mice
Microglia, and to a lesser extent macrophage, activation and accumulation in demyelinated
lesions is a hallmark feature in cuprizone-induced demyelination (Hiremath 2008; Hiremath
et al. 1998; McMahon et al. 2002). These cells phagocytize myelin debris as well as produce
a variety of cytokines and other molecules which may both exacerbate cuprizone-induced
demyelination, and promote the repair process (Arnett et al. 2001; Arnett et al. 2002; Iocca et
al. 2008; Irvine and Blakemore 2006; Mason et al. 2001b; Pasquini et al. 2007; Plant et al.
2005). Here, histochemical staining was performed with the lectin RCA-1, a marker for
microglia/macrophages, in the corpus callosum during the time course of demyelination and
remyelination. Very few microglia were present in mice that have not been exposed to
cuprizone, and this was not altered by E2 treatment (Figure 5). After three weeks of cuprizone
treatment, there were significantly fewer microglia in the demyelinated lesions of E2-treated
versus placebo-treated mice. However, by 5 weeks of cuprizone intoxication, there were similar
numbers of microglia present in placebo and E2-treated mice, despite the decreased
demyelination in E2-treated mice at this time point. An analysis of the E2 responders (filled
circles) indicated no clear pattern at the 3 week time point. However, there is a clear correlation
between fewer microglia and less demyelination at 5 weeks (Spearman correlation analysis; p
= 0.0048). During remyelination, the microglia population was diminished to a similar extent
in both placebo and E2-treated mice (Figure 5).
E2 does not affect the number of astrocytes during demyelination or remyelination
Astrocytes respond to demyelination and also secrete cytokines and growth factors that
participate in cuprizone-induced demyelination and remyelination (Komoly et al. 1992; Mason
et al. 2000a; Mason et al. 2000b; Plant et al. 2005; Plant et al. 2007; Selvaraju et al. 2004).
Similar to microglia, immunostaining with the astrocyte marker GFAP was performed to
examine whether E2 affects the numbers of these cells during demyelination and remyelination.
In the absence of cuprizone administration, there are few astrocytes present in the corpus
callosum (Figure 6). During demyelination, the astrocyte population increased similarly in
placebo and E2-treated mice at week 3 and week 5 (Figure 6). Furthermore, there appears to
be no obvious correlation with protection from demyelination (filled circles) and astrocyte
number at 3 weeks; however, at the 5 week time point, the E2 responders showed decreased
astrocyte accumulation. E2 had no effect on astrocyte numbers in the corpus callosum during
remyelination (Figure 6B).
TNFα and IGF-1 mRNA expression is diminished in E2-treated mice during demyelination
In an effort to identify potential mechanisms of E2 protection against cuprizone-induced
demyelination and oligodendrocyte loss, we measured the expression of specific for two
candidate mediators, TNFα and IGF-1 by real-time PCR. Due to the small amount of tissue
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from isolated corpus callosum and variability in E2-induced protection from demyelination
(Figure 2B), corpus callosi of 5 mice per group were pooled for RNA analysis. TNFα is an
inflammatory cytokine that has been associated both with exacerbation of demyelinating
disease (Arnett et al. 2001; Ito et al. 2001; Probert et al. 1995) as well as having an important
beneficial role in remyelination (Arnett et al. 2001). Furthermore, estrogen is known to reduce
TNFα expression in models of CNS injury/inflammation (Lin et al. 2009; Matejuk et al.
2001; Vegeto et al. 2006). Therefore, we sought to determine whether TNFα expression was
altered by E2 administration during cuprizone-induced demyelination or remyelination.
Previous studies have shown that TNFα is upregulated during cuprizone-induced
demyelination, and is primarily expressed by microglia, and occasionally by astrocytes (Arnett
et al. 2001). As expected, placebo-treated mice showed an increase in TNFα mRNA during
demyelination (70-fold compared to no cuprizone placebo at 3 weeks and 90-fold compared
to no cuprizone placebo at 5 weeks of cuprizone treatment (Figure 7A). During remyelination,
TNFα mRNA levels were reduced, which corresponds to the reduction in microglia and
astrocytes in both groups at this time point (Figure 5B). Interestingly, E2 treatment inhibited
TNFα induction during demyelination by approximately 33% at 3 weeks and 66% at 5 weeks
of cuprizone treatment compared to placebo. This reduction in TNFα induction occurs at the
same time points that higher numbers of surviving mature oligodendrocytes are observed in
E2-treated mice (Figure 3).
The second factor we measured is IGF-1, a growth factor expressed by most astrocytes and by
a subpopulation of microglia during cuprizone-induced demyelination (Mason et al. 2001b).
IGF-1 has also been demonstrated to promote oligodendrocyte survival and remyelination
(Mason et al. 2003; Mason et al. 2000b). Furthermore, there is evidence for cross-talk between
estrogen and IGF-1 effects in the CNS (Cardona-Gomez et al. 2001; Mendez et al. 2003;
Mendez et al. 2005). Therefore, we hypothesized that increased survival of oligodendrocytes
would be concomitant with increased expression of IGF-1. The data indicate that IGF-1 mRNA
expression increases during demyelination in placebo-treated mice (Figure 7B) and decreases
during remyelination, similar to previous results in unmanipulated mice subjected to cuprizone
intoxication (Mason et al. 2000a). However, when mice were exposed to E2 administration,
IGF-1 mRNA was substantially attenuated at both 3 and 5 weeks of demyelination (Figure
7B). Levels of IGF-1 receptor mRNA were not altered by E2 administration (data not shown).
This suppression of IGF-1, in addition to the suppression of TNFa, may indicate an overall
suppression of astrocytes and microglia by E2 administration.
DISCUSSION
The sex hormone E2 has been demonstrated to reduce neuronal loss and demyelination in
several models of CNS injury (Behl and Moosmann 2002; Hoffman et al. 2006; Pozzi et al.
2006; Tiwari-Woodruff et al. 2007), as well as prevent oligodendrocyte cell death and promote
proliferation of oligodendrocyte precursors in vitro (Gerstner et al. 2007; Marin-Husstege et
al. 2004; Takao et al. 2004). In this study, we used a toxin model of primary oligodendrocyte
death to evaluate the role of E2 in CNS demyelination and remyelination. We report that E2
administration to male mice partially ameliorated corpus callosum demyelination and reduced
mature oligodendrocyte loss. This protection was accompanied by a delay in microglia
accumulation in the demyelinating lesion as well as reduced IGF-1 and TNFα expression.
However, there was no statistically significant effect on the numbers of oligodendrocyte
precursors or astrocytes that infiltrated the lesion. In addition, E2 did not appear to alter
remyelination.
The two general mechanisms by which E2 may attenuate demyelination include a direct anti-
apoptotic effect on mature oligodendrocytes, or an anti-inflammatory mechanism acting on
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microglia and astrocytes. Both of these scenarios are plausible, given that E2 has been
demonstrated to prevent death of oligodendrocytes and neurons in vivo (Dubal et al. 1998;
Garcia-Segura et al. 1999; Gerstner et al. 2007; Quesada and Micevych 2004; Wen et al.
2004) as well as inhibit glial activation and inflammation in the CNS (Barreto et al. 2007;
Matejuk et al. 2001; Vegeto et al. 2003). Therefore, a combination of direct protection of mature
oligodendrocytes by E2 and reduced noxious products from microglia such as TNFα may
contribute to reduced demyelination.
Quantification of microglia and astrocytes during cuprizone-induced demyelination and
remyelination indicated that, overall, E2 delayed microglia accumulation, but had no effect on
astrocyte numbers in the corpus callosum. However, an analysis of the mice that showed the
greatest protection from demyelination by E2 indicated that there was a reduction in both of
these cell types, especially at the 5 week time point (Figures 5B and 6B, filled circles). In
addition to a delay in microglia accumulation at week 3 (Figure 5B), TNFα mRNA was reduced
in E2-treated mice (Figure 7A). If one assumes a similar reduction in protein levels, this
attenuation in a microglial response may be at least partially responsible for the protective
effect of E2, consistent with the delay in demyelination observed in TNFα-deficient mice
(Arnett et al. 2001).
Another potential mechanism to explain the increased survival of mature oligodendrocytes in
E2 treated mice (Figure 3) is a direct inhibition of oligodendrocyte apoptosis. E2 has been
shown to attenuate hyperoxia-induced apoptotic death of primary oligodendrocytes in vitro
through downregulation of proapoptotic mediators (Gerstner et al. 2007). Future studies to
measure expression of pro- and anti-apoptotic mediators localized to mature oligodendrocytes
may provide important insights into the mechanism of E2 protection in cuprizone-induced
demyelination.
Although E2 has been shown to increase proliferation of oligodendrocyte precursors in vitro
(Jung-Testas et al. 1992; Marin-Husstege et al. 2004), we did not observe an increase in the
numbers of OPCs in mice treated with E2 compared to placebo. In fact, E2-treated mice
exhibiting the most protection from demyelination also exhibited fewer OPCs in the lesion
compared to any of the other mice (Figure 4B, filled circles). The most likely interpretation
for this observation is that fewer OPCs were recruited into the lesion, because there was less
damage to the mature oligodendrocytes, and hence, less need for repair. This phenomenon has
been reported in IGF-1 transgenic mice (Mason et al. 2000b) and nNOS−/− mice (Linares et
al. 2006), in which there was very little loss of mature oligodendrocytes in the demyelinating
lesion, and subsequently very little accumulation of OPCs. Alternatively, the reduction of
TNFα in E2-treated mice may be at least partly responsible for diminished OPC numbers, given
that cuprizone-treated TNFα-deficient mice display a significant reduction in accumulation
and proliferation of OPCs during demyelination (Arnett et al. 2001). A third possible
explaination is that E2 may induce differentiation of OPCs, thus leading to the observation of
fewer OPCs and greater numbers of mature oligos at 5 weeks of cuprizone exposure in a subset
of the E2 treated mice (Figures 3B and 4B, filled circles). In summary, unlike in vitro studies,
E2 does not appear to increase OPC numbers in demyelinated lesions.
We have also demonstrated that E2-treatment attenuated demyelination-induced upregulation
of IGF-1 expression. IGF-1 is a survival factor for oligodendrocytes (Barres et al. 1993; Mason
et al. 2000b; Ye and D’Ercole 1999) and promotes remyelination (Mason et al. 2003). There
is evidence for cross-talk between the actions of estradiol and IGF-1 in several neural events,
including survival of developing neurons, neuronal differentiation, synaptic plasticity, female
sexual behavior, adult neurogenesis, and neuroprotection (reviewed in (Cardona-Gomez et al.
2001; Mendez et al. 2003; Mendez et al. 2005)). Therefore, we had originally hypothesized
that E2 administration may mediate a protective effect through the IGF-1 signalling pathway.
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In contrast, we found that E2 administration resulted in a diminished production of IGF-1
mRNA during demyelination. We were not able to assess IGF-1 protein levels from the corpus
callosum of mice with available antibodies for ELISA assay or Western blots. In the literature,
the effects of E2 on the expression of IGF-1 appear mixed, with a few reports that it results in
increased IGF-1 expression in various tissues (Michels et al. 1993; Murphy et al. 1987; Shingo
and Kito 2003) and others reporting a reduction (Borski et al. 1996; Durrer et al. 2007). We
and others have previously showed IGF-1 is primarily produced by microglia and astrocytes
(Mason et al. 2000; Komoly et al. 1992). The reduction of IGF-1 mRNA expression during
cuprizone-induced demyelination in our study may be secondary to reduced activation of
microglia and astrocytes, indicated by reduced TNFα expression (Figure 7A). In any case, the
protective effect of E2 does not appear to require upregulation of IGF-1 mRNA.
Expression of both estrogen receptor-alpha (ERα) and estrogen receptor-beta (ERβ) has been
demonstrated by a variety of methods in brain cells. Neurons and astrocytes can express either
ERα or ERβ in vivo (Garcia-Segura et al. 1999; Milner et al. 2001; Milner et al. 2005). ERβ is
co-localized on oligodendrocytes and the myelin sheath in vivo (Zhang et al. 2004); and ERα
has been demonstrated in microglia in vivo (Sierra et al. 2008). Experiments in our cuprizone
intoxication model to measure mRNA levels of ERα and ERβ during demyelination showed
no significant change compared to the no cuprizone control (data not shown). We did not detect
ERα by immunohistochemical staining in the corpus callosum, although positive cells were
found in regions of the brain known to express ERα such as the ventromedial hypothalamic
nucleus and arcuate nucleus (Merchenthaler et al. 2004; Mitra et al. 2003). We were unable to
detect the presence of ERβ due to nonspecific staining by available commercial antibodies.
Thus, is it not clear whether either or both ER type is required for the E2-mediated protection
from cuprizone-induced demyelination. Preliminary studies in our laboratory with ERα- and
ERβ-deficient mice indicate that ERα but not ERβ may be necessary for the protective effect
of E2 administration. This is partially consistent with findings in the EAE model, in which the
use of ERα or ERβ-deficient mice as well as selective agonists to each receptor, revealed that
the anti-inflammatory effects and the reduction in clinical symptoms by E2 administration was
mediated by ERα (Elloso et al. 2005; Garidou et al. 2004; Polanczyk et al. 2004). Interestingly,
these studies revealed that the E2 effect was not mediated through ERa expression on T cells
(Polanczyk et al. 2004), or any other bone marrow derived cells (Garidou et al. 2004), indicating
that E2 action on brain cells may be the critical factor. The cuprizone model, which does not
involve T cell mediated autoimmunity, may thus be an excellent model to continue studying
the mechanism involed in E2 mediated protection in demyelination pathology. Relatively little
attention has been paid to effects of E2 in oligodendrocytes in EAE studies. Here, we have
demonstrated that E2 can reduce demyelination and prevent the loss of oligodendrocytes in a
toxin model of demyelination (Figures 2, 3).
Recently, it was demonstrated that a combination of E2 and progesterone was successful in
reducing cuprizone-induced demyelination, although neither was effective when administered
alone (Acs et al. 2009). In our study, we used a higher dose of E2, and also a lower dose of
cuprizone than reported by Acs et al., perhaps allowing the moderate protection of E2 to become
apparent. Interestingly, this group found that the combined E2 and progestrerone therapy
resulted in an increase in microglia and astrocytes, as well as IGF-1 expression. We interpret
these findings to suggest that a combination of E2 and progesterone leads to accumulation of
gliosis, while E2 administration alone leads to decreased gliosis. However, both treatments
provide partial amelioration from demyelination.
In conclusion, we have demonstrated that E2 administration to male mice provides partial
protection from oligodendrocyte loss and demyelination. This protection may be due to a
combination of a delay in microglia accumulation and a reduction in TNFα mRNA expression.
This work adds to and expands the body of work indicating that estrogen can be beneficial
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therapy for CNS diseases such as multiple sclerosis and provides a basis for future experiments
designed to delineate the mechanism of E2 protection.
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Figure 1. Serum levels of E2 achieved using continuous release implants of E2 pellets in male mice
Serum was collected 4 days after subcutaneous implantation of 25 mg/60 day continuous
release E2 pellets (open diamonds), as well as at the time of sacrifice from mice that were not
exposed to cuprizone (open squares), or exposed to cuprizone for 3 weeks, 5 weeks (filled
circles, or 6 weeks plus 1 week of discontinuation of cuprizone (open circles). Measurement
of E2 in the serum was conducted by RIA. Results indicate that serum levels of E2 approached
the range reported for pregnant mice, and remained relatively constant during the entire time
course.
Taylor et al. Page 16













Figure 2. Demyelination and remyelination in placebo and E2-treated mice
A. Representative images of LFB-PAS-stained midline corpus callosum sections. The
corpus callosum is the area below the dashed white lines (except the 5wk images, in which the
entire image encompasses corpus callosum). Scale bar represents 50 micrometers.
B. Myelination scores obtained by blind-scoring of midline corpus callosum sections
stained with LFB-PAS. A score of 3 reflects normal myelination in an untreated mouse,
whereas a score of 0 reflects the absence of myelin. Individual data points (triangle and round
symbols) and mean values (horizontal bars) are plotted for 10–15 animals per group at each
time point. * p < 0.05. At the 3 and 5 week time points, E2-treated mice showing the greatest
protection from demyelination are indicated with filled circles so that they may be followed in
subsequent figures of this manuscript..
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Figure 3. Cuprizone-induced loss of oligodendrocytes and subsequent repopulation during
recovery in placebo and E2-treated mice
A. Representative images of GSTpi+ mature oligodendrocytes in the corpus callosum of
placebo and E2-treated mice during cuprizone administration and recovery. The inset in
the no cuprizone, placebo image shows an example of a GSTpi-positive cell (red, filled
arrowhead) overlayed with DAPI nuclei counterstain (blue, open arrowhead). DAPI overlayed
images were used for quantification. Scale bar represents 50 micrometers.
B. Quantification of GSTpi+ mature oligodendrocytes. Individual data points and mean bars
are plotted for 10–15 animals per group at each time point. * p < 0.05. At the 3 and 5 week
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time points, E2-treated mice that exhibited the greatest protection from demyelination (Figure
2B) are indicated with filled circles.
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Figure 4. Accumulation of OPCs during demyelination and remyelination in placebo and E2-
treated mice
A. Representative images of NG2+ OPCs in the corpus callosum of placebo and E2-treated
mice during cuprizone administration and recovery. The inset in the no cuprizone, placebo
image shows an example of an NG2-positive cell (red, filled arrowhead) overlayed with DAPI
nuclei counterstain (blue, open arrowhead). Images overlayed with DAPI were used for
quantification. Scale bar represents 50 micrometers.
B. Quantification of NG2+ OPCs. Individual data points and mean bars are plotted for 8–10
animals per group at each time point. There are no statistically significant differences between
placebo and E2-treated mice at any time point. At the 3 and 5 week time points, E2-treated
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mice that exhibited the greatest protection from demyelination (Figure 2B) are indicated with
filled circles.
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Figure 5. Accumulation of microglia during demyelination and remyelination in placebo and E2-
treated mice
A. Representative images of RCA-1+ microglia/macrophages in the corpus callosum of
placebo and E2-treated mice during cuprizone administration and recovery. The inset in
the 3wk cuprizone, placebo image shows an example of an RCA-1-positive cell (red, filled
arrowhead) overlayed with DAPI nuclei counterstain (blue, open arrowhead). DAPI-overlayed
images were used for quantification. Scale bar represents 50 micrometers.
B. Quantification of RCA-1+ microglia/macrophages. Individual data points and mean bars
are plotted for 10–15 animals per group at each time point. * p < 0.05. At the 3 and 5 week
time points, E2-treated mice that exhibited the greatest protection from demyelination (Figure
2B) are indicated with filled circles.
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Figure 6. Accumulation of astrocytes during demyelination and remyelination in placebo and E2-
treated mice
A. Representative images of GFAP+ astrocytes in the corpus callosum of placebo and E2-
treated mice during cuprizone administration and recovery. The inset in the 3wk
cuprizone, placebo image shows an example of a GFAP-positive cell (green, filled arrowhead)
overlayed with DAPI nuclei counterstain (blue, open arrowhead). DAPI-overlayed images
were used for quantification. Scale bar represents 50 micrometers.
B. Quantification of GFAP+ astrocytes. Individual data points and mean bars are plotted for
10–15 animals per group at each time point. There are no statistically significant differences
between placebo and E2-treated mice at any time point. At the 3 and 5 week time points, E2-
treated mice that exhibited the greatest protection from demyelination (Figure 2B) are indicated
with filled circles.
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Figure 7. Expression of TNFα and IGF-1 mRNA during demyelination and remyelination in
placebo and E2 treated mice
A. Real-time PCR analysis of TNFα mRNA. Results show the expected upregulation during
demyelination in placebo-treated mice, which is reduced by approximately half in E2-treated
mice. All samples are normalized to the no cuprizone placebo group.
B. Real-time PCR analysis of IGF-1 mRNA. Results show the expected upregulation during
demyelination in placebo-treated mice, which is dramatically reduced in E2-treated mice. All
samples are normalized to the no cuprizone placebo group.
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